<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049985</url>
  </required_header>
  <id_info>
    <org_study_id>20010170</org_study_id>
    <nct_id>NCT00049985</nct_id>
  </id_info>
  <brief_title>Heart Failure and Anemia</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance in Subjects With Symptomatic Heart Failure (CHF) and Anemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether increasing hemoglobin concentration in
      patients with heart failure and anemia will improve the patients' functional status,
      including exercise tolerance and New York Heart Association (NYHA) classification.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise tolerance</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>NYHA classification; patient-reported outcomes</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Heart Failure</condition>
  <condition>Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin Alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - At least 21 years of age - Symptomatic CHF for at least 3 months -
        Limited exercise tolerance on a treadmill - Reduced left ventricular ejection fraction -
        Stable heart failure medication - Hemoglobin concentration between 9.0 and 12.5 g/dL
        Exclusion Criteria: - Hypertension - Unstable angina pectoris or recent myocardial
        infarction - Likely to receive cardiac transplant - Unable to do cardiopulmonary exercise
        testing - Major organ transplant (e.g., lung, liver, heart) or in renal replacement therapy
        (e.g., dialysis) - Recent or current treatment for malignancy - Systemic hematologic
        disease - Anemia due to acute or chronic bleeding - Recent epogen or darbepoetin alfa
        therapy - Recent blood transfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P; Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008 Jan 29;117(4):526-35. doi: 10.1161/CIRCULATIONAHA.107.698514. Epub 2008 Jan 14.</citation>
    <PMID>18195176</PMID>
  </results_reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2002</study_first_submitted>
  <study_first_submitted_qc>November 18, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2002</study_first_posted>
  <last_update_submitted>August 6, 2009</last_update_submitted>
  <last_update_submitted_qc>August 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

